Screener
TG Therapeutics TGTX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Loss on extinguishment of debt | — | — | 9,153 | — |
| Other income | (5,132) | (2,793) | (7,519) | (6,396) |
| Total other expense | 11,440 | 3,923 | 25,872 | 7,077 |
| Net income before taxes | $10,234 | $30,920 | $30,597 | $36,388 |
| Income tax expense | (2,453) | (2,733) | (3,039) | (3,141) |
| Net income | $7,781 | $28,187 | $27,558 | $33,247 |
| Net income per common share: | ||||
| Basic | $0.05 | $0.19 | $0.19 | $0.23 |
Document
FAQ
- What is TG Therapeutics's pre-tax income?
- TG Therapeutics (TGTX) reported pre-tax income of $10.23M in Q2 2026.
- How has TG Therapeutics's pre-tax income changed year-over-year?
- TG Therapeutics's pre-tax income decreased by 66.9% year-over-year, from $30.92M to $10.23M.
- What is the long-term trend for TG Therapeutics's pre-tax income?
- Over 3 years (2021 to 2025), TG Therapeutics's pre-tax income has grown at a -32.4% compound annual growth rate (CAGR), from -$348.1M to $107.39M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about TG Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude